OFIX vs. SRDX, ANGO, ARAY, ATRC, ATEC, IART, IRMD, SIBN, BVS, and FNA
Should you be buying Orthofix Medical stock or one of its competitors? The main competitors of Orthofix Medical include Surmodics (SRDX), AngioDynamics (ANGO), Accuray (ARAY), AtriCure (ATRC), Alphatec (ATEC), Integra LifeSciences (IART), Iradimed (IRMD), SI-BONE (SIBN), Bioventus (BVS), and Paragon 28 (FNA). These companies are all part of the "surgical & medical instruments" industry.
Surmodics (NASDAQ:SRDX) and Orthofix Medical (NASDAQ:OFIX) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, media sentiment, risk, analyst recommendations, earnings, community ranking, institutional ownership, valuation and dividends.
Surmodics has a beta of 1.04, suggesting that its stock price is 4% more volatile than the S&P 500. Comparatively, Orthofix Medical has a beta of 1.06, suggesting that its stock price is 6% more volatile than the S&P 500.
Surmodics presently has a consensus target price of $57.00, indicating a potential upside of 64.74%. Orthofix Medical has a consensus target price of $18.00, indicating a potential upside of 20.00%. Given Orthofix Medical's stronger consensus rating and higher possible upside, equities research analysts plainly believe Surmodics is more favorable than Orthofix Medical.
In the previous week, Orthofix Medical had 2 more articles in the media than Surmodics. MarketBeat recorded 3 mentions for Orthofix Medical and 1 mentions for Surmodics. Surmodics' average media sentiment score of 0.34 beat Orthofix Medical's score of 0.00 indicating that Orthofix Medical is being referred to more favorably in the news media.
Surmodics has higher earnings, but lower revenue than Orthofix Medical. Orthofix Medical is trading at a lower price-to-earnings ratio than Surmodics, indicating that it is currently the more affordable of the two stocks.
96.6% of Surmodics shares are owned by institutional investors. Comparatively, 89.8% of Orthofix Medical shares are owned by institutional investors. 8.9% of Surmodics shares are owned by company insiders. Comparatively, 4.7% of Orthofix Medical shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Surmodics has a net margin of 9.44% compared to Surmodics' net margin of -16.64%. Orthofix Medical's return on equity of 13.30% beat Surmodics' return on equity.
Orthofix Medical received 74 more outperform votes than Surmodics when rated by MarketBeat users. However, 67.13% of users gave Surmodics an outperform vote while only 61.80% of users gave Orthofix Medical an outperform vote.
Summary
Surmodics beats Orthofix Medical on 12 of the 17 factors compared between the two stocks.
Get Orthofix Medical News Delivered to You Automatically
Sign up to receive the latest news and ratings for OFIX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding OFIX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Orthofix Medical Competitors List
Related Companies and Tools
